SUPPLEMENTARY TABLE 2

|  |  |  |
| --- | --- | --- |
|  | Lithium (n=31) | Placebo (n=30) |
| *Socio-demographic variables* |  |  |
| Age [a] years, mean (SD)  | 71.2 (5.4) \* | 74.4 (6.1) \* |
| Education [a]years, mean (SD)  | 9.47 (5.29) | 9.04 (4.74) |
| Gender [b]Female, %  | 74% | 63% |
| Ethnicity [c]Caucasian/Negroid/Asian (n) | 26 / 1 / 4 | 24 / 3 / 3 |
| *Cognitive and functional variables* |  |  |
| CDR=0.5 [b]number of cases (%) | 22 (71.0%) | 21 (70.0%) |
| CDR Sum of Boxes [a]mean score (SD); test range 0-18 § | 1.5 (1.3) | 1.7 (1.4)  |
| ADAS-Cog [a] mean total score (SD); test range 0-79 § | 10.9 (6.1) | 10.7 (5.4) |
| Delayed recall [a]mean score (SD); test range 0-10 #  | 4.6 (2.0) | 4.2 (2.4) |
| Figure recall [a]mean score (SD); test range 0-4 # | 2.3 (1.3) | 2.0 (1.2) |
| Trail Making Test-A [a]seconds (SD) § | 76.5 (49.1) | 85.6 (50.0) |
| Trail Making Test-B [a]seconds (SD) § | 176.6 (80.1) | 187.0 (79.1) |
| Sequence of Letters and Numbers [a]mean score (SD); test range 0-21 # | 6.5 (2.2) | 6.4 (1.9) |
| *Cerebrospinal fluid biomarkers (pg/ml)* |  |  |
| Amyloid-β1-42 [a]concentration, mean (SD) | 444.5 (156.4) | 429.2 (163.8) |
| Total Tau [a]concentration, mean (SD) | 92.8 (56.1) | 88.5 (49.9) |
| Phosphorylated Tau at threonine181 [a]concentration, mean (SD) | 63.8 (34.4) | 59.9 (29.0) |

CDR: Clinical Dementia Rating Scale; ADAS-Cog: Alzheimer’s Disease Assessment Scale, Cognitive Subscale; §: Higher values indicate worse performance; #: Higher values indicate better performance; SD: standard deviation; [a] Student’s t test (*t*); [b] Chi-squared test; [c] Fisher’s exact test. \* *t* (59), p=0.03; N.S. otherwise.